Axon Enterprise, Inc $AXON Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP raised its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 9.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,703 shares of the biotechnology company’s stock after purchasing an additional 3,123 shares during the period. Quantinno Capital Management LP’s holdings in Axon Enterprise were worth $15,588,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC purchased a new position in Axon Enterprise in the 4th quarter valued at about $480,000. NewEdge Advisors LLC boosted its holdings in Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after buying an additional 668 shares during the last quarter. Empowered Funds LLC increased its stake in Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after buying an additional 157 shares in the last quarter. Woodline Partners LP increased its stake in Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after buying an additional 2,003 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in shares of Axon Enterprise during the second quarter valued at approximately $284,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Buying and Selling at Axon Enterprise

In other news, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the transaction, the executive owned 49,710 shares in the company, valued at $24,855,000. The trade was a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $485.00, for a total transaction of $753,690.00. Following the transaction, the insider directly owned 34,024 shares in the company, valued at approximately $16,501,640. The trade was a 4.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 58,989 shares of company stock worth $30,527,983. Corporate insiders own 4.20% of the company’s stock.

Axon Enterprise Price Performance

AXON stock opened at $527.76 on Monday. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The firm has a market capitalization of $42.54 billion, a PE ratio of 211.95, a price-to-earnings-growth ratio of 10.77 and a beta of 1.39. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The business has a 50 day simple moving average of $497.09 and a 200-day simple moving average of $475.52.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The company had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.90 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.47 earnings per share. Equities research analysts anticipate that Axon Enterprise, Inc will post 1.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AXON. Barclays lowered their price target on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. UBS Group reduced their price objective on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. The Goldman Sachs Group set a $535.00 price objective on Axon Enterprise in a report on Thursday, May 7th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Finally, Morgan Stanley set a $600.00 target price on shares of Axon Enterprise in a report on Thursday, May 7th. Fifteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus target price of $725.25.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.